Evidence map›Paper›PMID 41988363›Full record

ArticleACS pharmacology & translational science2026

l‑Boronophenylalanine (l-BPA) Dipeptide Prodrugs Enhance Boron Delivery to Tumors, Facilitate Tumor Eradication and Induce Tumor Vaccine Effect in Mice Following Neutron Irradiation.

Michael Torgov, Arthur Raitano, Jason Cole Quintana, Tioga Martin, Leila Kulenovic, Samkeliso Dlamini, Chunying Zhang, Maria-Christina Malinao, Maki Ikeura, Linnette Capo and 10 more

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Michael TorgovTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.ORCID https://orcid.org/0009-0006-6094-5606
Arthur RaitanoTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.ORCID https://orcid.org/0000-0002-6581-0704
Jason Cole QuintanaTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Tioga MartinTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Leila KulenovicTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Samkeliso DlaminiTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Chunying ZhangTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Maria-Christina MalinaoTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Maki IkeuraTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Linnette CapoTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Karen MorrisonTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Kotaro MatsumotoInstitute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University, Yoshida Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0002-4927-0103
Aoi KomatsuInstitute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University, Yoshida Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0003-2322-8692
Yuya HigashiInstitute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University, Yoshida Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Takata TakushiInstitute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan.
Yoshinori SakuraiInstitute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan.ORCID https://orcid.org/0000-0001-9404-4255
Robert DornTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.
Minoru SuzukiInstitute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan.ORCID https://orcid.org/0000-0002-5421-9417
Fuyuhiko TamanoiInstitute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University, Yoshida Ushinomiya-cho, Sakyo-ku, Kyoto 606-8501, Japan.ORCID https://orcid.org/0000-0002-4220-6408
Kendall MorrisonTAE Life Sciences, Drug Development Division, 1756 Cloverfield Blvd., Santa Monica, California 90404, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Boron neutron capture therapy (BNCT) is an emerging cancer treatment modality that has seen a resurgence due to its efficacy and the advent of compact neutron beam devices. BNCT is a binary cancer treatment that combines selective boron delivery with epithermal neutron irradiation. When

Indexed as

10B-dipeptidesBNCTl-Ala-BPAl-BPA-BPA

Identifiers

PMID41988363
PMCPMC13077494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.